AML Labs Explained
What Blood and Bone Marrow Tests Reveal After Diagnosis
After an acute myeloid leukemia (AML) diagnosis, treatment often begins right away—leaving little time to process what’s happening, let alone what your lab results mean.
In this discussion, AML survivor Steve Buechler speaks with Dr. Alice Mims from The Ohio State University Comprehensive Cancer Center about the key blood and bone marrow tests that guide treatment, track progress, and inform long-term decisions. From CBCs and blast counts to FLT3 and NPM1 mutations, they break down what you need to know moving forward.
Program Topics
- Learn what your CBC results mean—including white blood cells, hemoglobin, and platelet counts
- Understand what blast cells are and why they matter in AML
- Hear how bone marrow biopsies and genetic testing (like FLT3 or NPM1) shape your treatment
- Get guidance on monitoring your bloodwork during treatment and remission
- Know when to consider clinical trials and how MRD tracking may guide next steps
Program Panel
Program Partner
Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
This is not medical advice. Please consult with your healthcare provider to make informed treatment decisions.
This interview has been edited for clarity and length. The views and opinions expressed in this interview do not necessarily reflect those of The Patient Story. This content does not replace professional medical advice.
Hear from people living with acute myeloid leukemia (AML)
Real experiences with diagnosis, treatment choices, side effects, and life beyond AML — in their own words.
